

GÃ©rard Zalcman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2559246/publications.pdf>

Version: 2024-02-01

153
papers

18,355
citations

47006

47
h-index

12946

131
g-index

173
all docs

173
docs citations

173
times ranked

22720
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. <i>Journal of Thoracic Oncology</i> , 2022, 17, 239-251.	1.1	51
2	Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. <i>European Journal of Cancer</i> , 2022, 162, 182-193.	2.8	40
3	Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 719-728.	1.6	37
4	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 104-114.	10.7	123
5	SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents. <i>JAMA Oncology</i> , 2022, 8, 612.	7.1	35
6	Intestinal <i>Akkermansia muciniphila</i> predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	30.7	225
7	Measuring Walking Speed Failed to Predict Early Death and Toxicity in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) Selected for Undergoing First-Line Systemic Treatment: An Observational Exploratory Study. <i>Cancers</i> , 2022, 14, 1344.	3.7	3
8	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	2.0	9
9	The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6042.	4.1	1
10	Systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of patients with cancer treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2585-2585.	1.6	0
11	Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre Areal-life cohort study. <i>European Journal of Cancer</i> , 2022, 173, 33-40.	2.8	5
12	The STK38-XPO1 axis, a new actor in physiology and cancer. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 1943-1955.	5.4	8
13	In vitro bone metastasis dwelling in a 3D bioengineered niche. <i>Biomaterials</i> , 2021, 269, 120624.	11.4	17
14	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 397, 375-386.	13.7	638
15	Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms. <i>Cancers</i> , 2021, 13, 643.	3.7	19
16	Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. <i>European Journal of Cancer</i> , 2021, 145, 179-182.	2.8	9
17	Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. <i>Cancers</i> , 2021, 13, 1040.	3.7	13
18	Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. <i>Rheumatology</i> , 2021, 60, 5753-5764.	1.9	17

#	ARTICLE	IF	CITATIONS
19	National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma?. <i>Cancer</i> , 2021, 127, 2181-2183.	4.1	2
20	Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screening. <i>Diagnostic and Interventional Imaging</i> , 2021, 102, 199-211.	3.2	10
21	Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9015-9015.	1.6	8
22	Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. <i>European Journal of Cancer</i> , 2021, 151, 252-253.	2.8	1
23	Heterogeneity of treatment effects in malignant pleural mesothelioma – Authors' reply. <i>Lancet</i> , The, 2021, 398, 302.	13.7	2
24	Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway. <i>Lung Cancer</i> , 2021, 160, 28-31.	2.0	7
25	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial. <i>Lung Cancer</i> , 2021, 164, 84-90.	2.0	0
26	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 829-840.	3.0	25
27	Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2020, 20, 1186.	2.6	8
28	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). <i>European Journal of Cancer</i> , 2020, 141, 62-81.	2.8	122
29	Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	3.2	42
30	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. <i>European Journal of Cancer</i> , 2020, 131, 27-36.	2.8	44
31	NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1147-1159.	1.1	88
32	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. <i>PLoS ONE</i> , 2020, 15, e0243961.	2.5	15
33	Title is missing!. , 2020, 15, e0243961.		0
34	Title is missing!. , 2020, 15, e0243961.		0
35	Title is missing!. , 2020, 15, e0243961.		0
36	Title is missing!. , 2020, 15, e0243961.		0

#	ARTICLE	IF	CITATIONS
37	<scp>STK</scp> 38 kinase acts as <scp>XPO</scp> 1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes. EMBO Reports, 2019, 20, e48150.	4.5	34
38	Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Nonâ€‘small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). Clinical Lung Cancer, 2019, 20, 222-230.	2.6	3
39	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. Clinical Cancer Research, 2019, 25, 5759-5765.	7.0	13
40	Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas. Journal of Molecular Diagnostics, 2019, 21, 695-704.	2.8	11
41	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Clinical Lung Cancer, 2019, 20, e564-e575.	2.6	49
42	Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung Cancer, 2019, 132, 65-71.	2.0	120
43	NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 158.	8.6	22
44	MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. British Journal of Cancer, 2019, 120, 387-397.	6.4	19
45	RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome. Journal of Thoracic Oncology, 2019, 14, e250-e251.	1.1	1
46	RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasisâ€‘an updated review. Cell Death and Disease, 2019, 10, 928.	6.3	51
47	Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial. Cancers, 2019, 11, 1835.	3.7	4
48	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncology, The, 2019, 20, 239-253.	10.7	342
49	Immunotherapy in relapsed mesothelioma. Immunotherapy, 2018, 10, 77-80.	2.0	5
50	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer, 2018, 123, 14-21.	2.0	21
51	Cost-effectiveness of <i>KRAS</i>, <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. European Respiratory Journal, 2018, 51, 1701467.	6.7	16
52	Gut microbiome influences efficacy of PD-1â€‘based immunotherapy against epithelial tumors. Science, 2018, 359, 91-97.	12.6	3,689
53	Lazarus Syndrome With Crizotinib in a Nonâ€‘Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation. Clinical Lung Cancer, 2018, 19, e57-e61.	2.6	5
54	A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control. Cell Communication and Signaling, 2018, 16, 66.	6.5	28

#	ARTICLE	IF	CITATIONS
55	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	7.1	567
56	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. <i>British Journal of Cancer</i> , 2017, 116, 1505-1512.	6.4	25
57	Bevacizumab in advanced lung cancer: state of the art. <i>Future Oncology</i> , 2017, 13, 2515-2535.	2.4	53
58	A review of bevacizumab in the treatment of malignant pleural mesothelioma. <i>Future Oncology</i> , 2017, 13, 2537-2546.	2.4	14
59	Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment. <i>European Respiratory Journal</i> , 2017, 50, 1700310.	6.7	21
60	Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. <i>Respiratory Research</i> , 2017, 18, 120.	3.6	41
61	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 1403-1410.	1.6	277
62	MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial. <i>Oncotarget</i> , 2017, 8, 4313-4329.	1.8	16
63	Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. <i>European Respiratory Journal</i> , 2016, 48, 861-872.	6.7	17
64	Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?. <i>European Respiratory Journal</i> , 2016, 47, 1890-1891.	6.7	1
65	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). <i>Lancet, The</i> , 2016, 387, 1415-1426.	13.7	790
66	RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway. <i>Cancer Research</i> , 2016, 76, 1627-1640.	0.9	92
67	ROS-1 rearrangements in non-small cell lung cancer (NSCLC): a new target for a small subset of patients but a giant leap in therapeutics. <i>Current Pulmonology Reports</i> , 2016, 5, 57-62.	1.3	1
68	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 1405-1414.	13.7	753
69	Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients. <i>European Journal of Cancer</i> , 2016, 52, 120-128.	2.8	42
70	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1451-1457.	1.1	141
71	Do atmospheric conditions influence the first episode of primary spontaneous pneumothorax?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015, 21, 296-300.	1.1	13
72	ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 225-233.	2.4	9

#	ARTICLE	IF	CITATIONS
73	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. <i>European Respiratory Journal</i> , 2015, 45, 1403-1414.	6.7	66
74	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology</i> , 2015, 16, 257-265.	10.7	1,269
75	Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). <i>Lung Cancer</i> , 2015, 89, 139-145.	2.0	10
76	No impact of passive smoke on the somatic profile of lung cancers in never-smokers. <i>European Respiratory Journal</i> , 2015, 45, 1415-1425.	6.7	27
77	Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. <i>Annals of Oncology</i> , 2015, 26, 908-914.	1.2	81
78	Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. <i>Journal of Clinical Oncology</i> , 2015, 33, 992-999.	1.6	326
79	Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504. <i>European Respiratory Journal</i> , 2015, 46, 1440-1450.	6.7	7
80	Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence. <i>Journal of Clinical Oncology</i> , 2015, 33, 2930-2931.	1.6	15
81	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. <i>Nature Genetics</i> , 2015, 47, 1200-1205.	21.4	252
82	First-in-human phase I administration of YS110, a monoclonal antibody directed against the CD26 immunostimulatory molecule in advanced cancer patients. <i>Journal of Clinical Oncology</i> , 2015, 33, 2519-2519.	1.6	0
83	Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1266-1267.	0.8	17
84	Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. <i>BMC Cancer</i> , 2014, 14, 953.	2.6	12
85	Reply to letter. <i>European Journal of Cancer</i> , 2014, 50, 678.	2.8	0
86	A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 2156-2162.	1.2	26
87	Retrospective observational study of diagnostic accuracy of the Xpert [®] MTB/RIF assay on fiberoptic bronchoscopy sampling for early diagnosis of smear-negative or sputum-scarce patients with suspected tuberculosis. <i>BMC Pulmonary Medicine</i> , 2014, 14, 137.	2.0	45
88	Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. <i>Annals of Oncology</i> , 2014, 25, 126-131.	1.2	270
89	A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting-IFCT/ERMETIC2 Project Part 1. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 45-55.	2.8	31
90	Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002. <i>Clinical Cancer Research</i> , 2014, 20, 4613-4624.	7.0	195

#	ARTICLE	IF	CITATIONS
91	A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer, 2014, 14, 231.	2.6	19
92	Customized Adjuvant Phase II Trial in Patients With Non-“Small-Cell Lung Cancer: IFCT-0801 TASTE. Journal of Clinical Oncology, 2014, 32, 1256-1261.	1.6	66
93	Second-line therapy in elderly patients with advanced nonsmall cell lung cancer. European Respiratory Journal, 2014, 43, 240-249.	6.7	10
94	Abstract CT209: A phase I study with the oral pan-CDK inhibitor BAY 1000394 in patients with advanced stage small cell lung or ovarian cancer. , 2014, , .		1
95	Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.. Journal of Clinical Oncology, 2014, 32, 11035-11035.	1.6	4
96	Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.. Journal of Clinical Oncology, 2014, 32, 7505-7505.	1.6	1
97	National multidisciplinary tumor board (MTB): Report of the first 526 questions raised within RYTHMIC, the network for thymic malignancies in France.. Journal of Clinical Oncology, 2014, 32, 7605-7605.	1.6	0
98	Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial.. Journal of Clinical Oncology, 2014, 32, 7511-7511.	1.6	0
99	Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infectious Diseases, 2013, 13, 435.	2.9	11
100	A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). European Journal of Cancer, 2013, 49, 2654-2664.	2.8	47
101	Does Bilobectomy Offer Satisfactory Long-Term Survival Outcome for Non-Small Cell Lung Cancer?. Annals of Thoracic Surgery, 2013, 95, 1726-1733.	1.3	6
102	Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy. European Respiratory Review, 2013, 22, 565-576.	7.1	23
103	From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue franÃ§aise (GOLF). Annals of Oncology, 2013, 24, 586-597.	1.2	88
104	<i>In vivo</i>probe-based confocal laser endomicroscopy in amiodarone-related pneumonia. European Respiratory Journal, 2013, 42, 1646-1658.	6.7	38
105	Topics in thoracic oncology: from surgical resection to molecular dissection. European Respiratory Review, 2013, 22, 101-102.	7.1	3
106	Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study. Journal of Thoracic Oncology, 2013, 8, 906-914.	1.1	12
107	Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 8000-8000.	1.6	70
108	An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial. Clinical Cancer Research, 2012, 18, 2976-2986.	7.0	52

#	ARTICLE	IF	CITATIONS
109	Impact of Point Spread Function Reconstruction on Thoracic Lymph Node Staging With 18F-FDG PET/CT in Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 971-976.	1.3	53
110	Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group. <i>Journal of Thoracic Oncology</i> , 2012, 7, 599-606.	1.1	43
111	Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non-Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized Trials. <i>Journal of Thoracic Oncology</i> , 2012, 7, 841-849.	1.1	104
112	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project Part 2). <i>Journal of Thoracic Oncology</i> , 2012, 7, 1490-1502.	1.1	69
113	High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non-Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1203-1213.	4.1	77
114	A STEPP too far for FLEX?. <i>Lancet Oncology</i> , The, 2012, 13, e51.	10.7	1
115	Lung cancer in never smokers – A review. <i>European Journal of Cancer</i> , 2012, 48, 1299-1311.	2.8	694
116	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3516-3524.	1.6	214
117	Observational Study of QuantiFERON®-TB Gold In-Tube Assay in Tuberculosis Contacts in a Low Incidence Area. <i>PLoS ONE</i> , 2012, 7, e43520.	2.5	17
118	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. <i>Circulation</i> , 2012, 125, 2128-2137.	1.6	548
119	Prognostic value of pathologic complete response to preoperative chemotherapy in early-stage non small cell lung cancer: Combined analysis of two IFCT randomized trials.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7057-7057.	1.6	0
120	Myocardial Strain Assessment in Cystic Fibrosis. <i>Journal of the American Society of Echocardiography</i> , 2011, 24, 1037-1045.	2.8	24
121	Chemotherapy in elderly patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 364-368.	2.0	24
122	Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. <i>Lancet</i> , The, 2011, 378, 1079-1088.	13.7	521
123	Evaluation of current practice. <i>Anti-Cancer Drugs</i> , 2011, 22, 919-925.	1.4	15
124	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. <i>Medicine (United States)</i> , 2011, 90, 201-211.	1.0	60
125	Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Tj ETQq1 1 0.78#314 rgBZ /Overbo 1006-1015.	1.0	15
126	Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2011, 37, 183-193.	6.7	37

#	ARTICLE	IF	CITATIONS
127	Admission of advanced lung cancer patients to intensive care unit: A retrospective study of 76 patients. <i>BMC Cancer</i> , 2011, 11, 159.	2.6	58
128	Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 106-111.	2.4	12
129	Osteoblastic Reaction in Non-small Cell Lung Carcinoma and its Association to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Response and Prolonged Survival. <i>Journal of Thoracic Oncology</i> , 2010, 5, 491-496.	1.1	51
130	Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). <i>Lung Cancer</i> , 2010, 70, 301-307.	2.0	40
131	La recherche clinique en cancérologie thoracique: place et rôle de l'Intergroupe francophone de cancérologie thoracique (IFCT). <i>Oncologie</i> , 2009, 11, 343-347.	0.7	0
132	Gefitinib plus docetaxel in non-small-cell lung cancer. <i>Lancet</i> , The, 2009, 373, 541.	13.7	3
133	Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin en 2008. <i>Oncologie</i> , 2008, 10, 545-550.	0.7	1
134	Breathing-Swallowing Interaction in Neuromuscular Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 269-276.	5.6	76
135	Long-term results of endobronchial brachytherapy: A curative treatment?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 425-430.	0.8	56
136	Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1026-1032.	6.4	42
137	Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 351-360.	27.0	2,161
138	Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m ²) as second-line monotherapy for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2004, 15, 38-44.	1.2	36
139	Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array. <i>Clinical Cancer Research</i> , 2004, 10, 3479-3489.	7.0	277
140	RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. <i>Experimental Cell Research</i> , 2003, 291, 363-376.	2.6	94
141	Detection of p53 antibodies in patients with various types of cancer: immunological characterization. <i>British Journal of Cancer</i> , 2001, 84, 57-63.	6.4	19
142	Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. <i>International Journal of Cancer</i> , 2000, 89, 81-86.	5.1	40
143	A Misleading Pulmonary Lesion in a Patient with Acute Monoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2000, 37, 457-459.	1.3	0
144	Interaction of the Grb7 adapter protein with Rnd1, a new member of the Rho family. <i>FEBS Letters</i> , 2000, 467, 91-96.	2.8	24

#	ARTICLE	IF	CITATIONS
145	Quantitative Fluorescence in Situ Hybridization in Lung Cancer as a Diagnostic Marker. <i>Journal of Molecular Diagnostics</i> , 1999, 1, 33-37.	2.8	8
146	RhoGAPs and RhoGDIs, (His)stories of Two Families. <i>Progress in Molecular and Subcellular Biology</i> , 1999, 22, 85-113.	1.6	33
147	The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis. , 1998, , 221-230.		0
148	Fluoxetine-induced pulmonary granulomatosis. <i>European Respiratory Journal</i> , 1996, 9, 615-617.	6.7	23
149	RhoGDI-3 Is a New GDP Dissociation Inhibitor (GDI). <i>Journal of Biological Chemistry</i> , 1996, 271, 30366-30374.	3.4	107
150	Serum p53 antibodies as early markers of lung cancer. <i>Nature Medicine</i> , 1995, 1, 701-702.	30.7	293
151	Prolonged Survival After High-Dose Rate Endobronchial Radiation for Malignant Airway Obstruction. <i>Chest</i> , 1994, 105, 767-772.	0.8	93
152	Detection and Sequencing of p53 Gene Mutations in Bronchial Biopsy Samples in Patients With Lung Cancer. <i>Chest</i> , 1994, 106, 1309-1310.	0.8	0
153	Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. <i>British Journal of Cancer</i> , 1994, 69, 809-816.	6.4	141